Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Zhongguo Dang Dai Er Ke Za Zhi ; 14(2): 110-3, 2012 Feb.
Artículo en Chino | MEDLINE | ID: mdl-22357467

RESUMEN

OBJECTIVE: To study the status of iron deposition in patients with ß-thalassemia intermedia and major in mainland China. METHODS: The status of transfusion and chelation was examined in 39 patients with ß-thalassemia intermedia or major. Serum ferritin levels were measured. MRI T2* technique was used to detect cardiac and hepatic iron deposition. RESULTS: Serum ferritin levels ranged from the minimum of 1500 ng/mL up to a maximum of 11491 ng/mL. From liver MRI T2* measurement, 15 cases had severe hepatic iron deposition (38%) and moderate deposition was found in 15 cases (38%), mild in 7 cases (18%), and normal in 2 cases (5%). Heart MRI T2* showed severe heart iron deposition in 7 cases (18%), mild in 5 cases (13%), and normal in 27 cases (69%). One case had cardiac arrhythmia. Four cases were over 20 years of age, and presented with gonadal function hypoplasia. The majority of patients did not receive regular transfusion and they had delayed, suboptimal chelation due to financial problems. Serum ferritin level was closely related with timing and dosage of chelation. CONCLUSIONS: In patients with ß-thalassemia who do not receive early regular transfusion and iron chelation therapy, iron deposition may occur at an early age. Important organs and tissue functional lesions and related complications also result. Relevant agencies and family members should be aware of this trend and develop appropriate strategies to improve the medical condition and quality of life of patients with this disorder.


Asunto(s)
Hierro/metabolismo , Hígado/metabolismo , Imagen por Resonancia Magnética/métodos , Miocardio/metabolismo , Talasemia beta/metabolismo , Adolescente , Adulto , Transfusión Sanguínea , Niño , Femenino , Ferritinas/sangre , Humanos , Masculino , Talasemia beta/terapia
2.
Hemoglobin ; 33(5): 296-303, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19814675

RESUMEN

According to the data from different screening studies, thalassemia is the most commonly seen hereditary hemolytic disease in China. The reported prevalence of thalassemia carriers varies but it is most prevalent in Southern China. In the past, the outcome of patients with thalassemia major has been very poor due to unfavorable economic background. With economic improvement in the past 10 years, increasing number of patients can get regular transfusion and chelation, and more patients can be treated by hemopoietic stem cell transplantation. A better prevention network has been built up over the years, but there are still babies being born with severe forms of thalassemia every year. A more comprehensive preventive program and public education are vital.


Asunto(s)
Quelantes del Hierro/uso terapéutico , Talasemia beta/tratamiento farmacológico , Talasemia beta/epidemiología , Transfusión Sanguínea , China/epidemiología , Trasplante de Células Madre Hematopoyéticas , Humanos , Incidencia , Medicina Tradicional China , Diagnóstico Prenatal , Prevalencia , Talasemia beta/diagnóstico , Talasemia beta/etnología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA